ViscumTT reduces the growth of human Ewing sarcoma xenograft tumors in mice.
Figures are generally photos, graphs and static images that would be represented in traditional pdf publications.
Established Ewing sarcoma xenograft tumors were intratumorally (i.t.) injected with 40/50/60mg oleanolic acid/kg mouse weight (TT i.t.), 0.75/1.25/1.75μg mistletoe lectin /kg mouse weight (viscum i.t.) or a combination thereof (viscumTT i.t.) every 2 to 3 days in increasing concentrations. Each concentration was administered twice within 2–3 days. One treatment group received viscumTT intravenously (i.v.), and one positive control group was once intravenously (i.v.) treated with 4 mg/kg doxorubicin. The negative control group received the solubilizing agent, cyclodextrins (CD), which was injected either intratumorally (CD i.t.) or intravenously (CD i.v.). One-way ANOVA revealed a significant group effect (p = 0.007) and Fisher´s Least Significant Difference test comparing all groups with all groups showed a significant effect between the CD i.t. control group and viscumTT i.t. (p = 0.033), viscum i.t. (p = 0.002) and TT i.t. (p = 0.021) as well as between the CD i.v. control group and viscumTT i.v. (p = 0.014) or the positive control group, doxorubicin i.v. (p = 0.015). Box-and-wisker plots each represent one treatment group including 8 mice (*p < 0.05, **p < 0.005).